Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model

Discussion: There is enormous potential for cost savings in the US market for generic cardiology drugs. By encouraging increased competition, decreasing administrative costs, and advocating for our patients to compare prices between the MCCPDC and other generic pharmaceutical dispensers, we have the potential to improve access to care and corresponding outcomes for cardiology patients.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research